Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.
Kazia’s CEO Dr James Garner gave an overview of the company’s achievements over the past year, including recent out-licensing agreements and an update on the current clinical trials of the company’s therapies Cantrixil (for recurrent ovarian cancer) and GDC-0084 (for the brain cancer glioblastoma multiforme).
A webcast of the Sydney presentation, including the presentation notes, is here. Note that the presentation has been edited for running time.
